DiscoverDaily Medical NewsAFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes
AFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes

AFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes

Update: 2019-11-15
Share

Description

ATTEST: AFib ablation slows progression to persistence

By Mitchel Zoler

 

AFib ablation cut the rate of paroxysmal to persistent arrhythmia progression by 89%, compared with medical management.

 

You can take the MDedge Podcasts survey by clicking here.

 

Other stories:

 

FDA panel rejects new empagliflozin indication for type 1 diabetes

Panelists voted 14-2 against the application and criticized the limited data supporting the application.

 

ACP recommends ways to address rising drug prices

One of the College’s suggestions is for the Medicare Part D low-income subsidy program to be modified.

 

Drug spending driving up Part B premiums and deductibles

The standard premium will climb 6.7% in 2020.

 

Methotrexate affected joint erosions, not pain, in patients with erosive hand OA

The results were observed for 10 mg methotrexate per week at 3 months and 12 months.

 

You can contact the MDedge Daily Medical News by emailing us at podcasts@mdedge.com or following us on Twitter at @MDedgeTweets.

Comments 
loading
In Channel
loading
Download from Google Play
Download from App Store
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

AFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes

AFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes

MDedge